Month: September 2020
Stockholm, Sverige, 28 september 2020 – Hoylu, ledande inom visuella samarbetslösningar för distribuerade team, tillkännagav idag det omedelbara tillskottet av två kraftfulla nya funktioner i Hoylu-workspaces för alla användare. Voting (röstning) och Timer är tillgängliga nu för alla registrerade Hoylu-användare, och utökar därmed funktionaliteten för nya och befintliga arbetsytor.Timerfunktionen tillåter synkronisering av uppgifter och projekt genom att användarna kan lägga till en flexibel timer till alla arbetsytor som räknar ned till en deadline för alla användare. Timers kvarstår utanför aktiv användning, vilket gör det effektivt om kort eller lång tid ska brukas, eller helt enkelt att sätta en tidsram för en specifik uppgift för att uppnå effektivitet.För att se en video om denna nya funktionalitet, besök Hoylu videokanal eller...
SCOR welcomes A.M. Best’s decision to confirm its Financial Strength Rating of ‘A+ Superior’ and its Issuer Credit Rating of ‘aa-’
Written by Customer Service on . Posted in Public Companies.
Press ReleaseSeptember 28, 2020 – N° 21SCOR welcomes A.M. Best’s decision to confirm itsFinancial Strength Rating of ‘A+ Superior’and its Issuer Credit Rating of ‘aa-’A.M. Best has decided to affirm SCOR’s Financial Strength Rating of ‘A+ (Superior)’ and its Long-Term Issuer Credit Rating of ‘aa-’.According to A.M. Best, this decision reflects “SCOR’s balance sheet strength, which A.M. Best categorises as very strong, as well as its strong operating performance, very favourable business profile and very strong enterprise risk management.”Indeed, A.M. Best recognises that “SCOR’s balance sheet strength is underpinned by risk-adjusted capitalisation that exceeds the level required to support the strongest assessment, as measured by Best’s Capital Adequacy Ratio.” A.M. Best expects “risk-adjusted capitalisation to be maintained at...
SCOR salue la décision de A.M. Best de confirmer la note de solidité financière du Groupe à « A+ (Supérieure) » et sa note de crédit émetteur à « aa- »
Written by Customer Service on . Posted in Public Companies.
Communiqué de presse28 septembre 2020 – N° 21SCOR salue la décision de A.M. Best de confirmer la note de solidité financière du Groupe à « A+ (Supérieure) » et sa note de crédit émetteur à « aa- »L’agence A.M. Best a décidé de confirmer la note de solidité financière du groupe SCOR à « A+ (Supérieure) » et sa note de crédit émetteur à « aa- ».Pour A.M. Best, cette décision reflète : « la solidité du bilan de SCOR, jugée très élevée, ainsi qu’une performance opérationnelle forte, un fonds de commerce très solide et un risk management de très haut niveau ».A.M. Best reconnaît que « la solidité du bilan de SCOR est confortée par un niveau de capital ajusté du risque – mesuré par le ratio de capitalisation Best’s Capital Adequacy Ratio – qui se situe au niveau le plus élevé ». A.M. Best anticipe que « le niveau de capital ajusté du...
Victory Square Technologies Portfolio Company receives an order of Safetest Covid-19 Testing Kits from North America’s TM Safety Supplies Company
Written by Customer Service on . Posted in Public Companies.
Victory Square Health Receives an order of 2,000,000 units of Safetest Covid-19 Testing Kits subject to Health Canada approvalVictory Square Health to be exclusive supplier of its proprietary Safetest products to TM Safety Supplies of CanadaThis order and potential subsequent orders is subject to Health Canada approvalTM Safety Supplies is a North American supplier of health and safety equipment including PPE protection to some of North America’s largest manufacturers. Based in Toronto, Ontario, TM Safety Supplies clients include Nestle, CIBC Bank, and Sysco to name a fewVANCOUVER, British Columbia, Sept. 27, 2020 (GLOBE NEWSWIRE) — Victory Square Health Inc. (“VS Health” or the “Company”) – a portfolio company of Victory Square Technologies Inc. (“Victory Square”) (CSE:VST) (OTC:VSQTF) (FWB:6F6) is pleased...
WCP B Move Update: Plant Relocated Safely to Pilivili
Written by Customer Service on . Posted in Public Companies.
Kenmare Resources plc (“Kenmare” or “the Company”)28 September 2020WCP B Move Update: Plant Relocated Safely to PiliviliKenmare Resources plc (LSE:KMR, ISE:KMR), one of the leading global producers of titanium minerals and zircon, which operates the Moma Titanium Minerals Mine in northern Mozambique, is pleased to announce that Wet Concentrator Plant (“WCP”) B has been relocated safely to Pilivili.Kenmare previously announced three development projects that together have the objective of increasing annual ilmenite production to 1.2 million tonnes (plus co-products) on a sustainable basis from 2021. The move of WCP B to the high grade Pilivili ore zone is the final of the three projects. This increased production is expected to significantly lower cash operating costs to between US$125 and US$135 per tonne (in 2020 real terms). Consequently,...
Exercise of Warrants
Written by Customer Service on . Posted in Public Companies.
Providence Resources P.l.c.Exercise of WarrantsDublin and London – 28 September 2020 – Providence Resources P.l.c. (PVR LN, PRP ID), the Irish based resource development company (“Providence” or the “Company”), announces that 16,433,333 warrants of 3p each have been exercised raising £492,999.99 for the Company. The warrants were issued as part of the fundraising in May 2020.Providence Resources has issued a total of 16,433,333 new Ordinary Shares (the “New Ordinary Shares
ArcelorMittal unlocks value through separation of integrated US assets and repositions its footprint in North America
Written by Customer Service on . Posted in Public Companies.
28 September 2020, 07:45 CETArcelorMittal (the “Company”, “Group”) announces it has entered into a definitive agreement (the “Agreement”) with Cleveland-Cliffs Inc. (“Cleveland-Cliffs”) pursuant to which Cleveland-Cliffs will acquire 100% of the shares of ArcelorMittal USA (the “Transaction”) for a combination of cash and stock. Transaction HighlightsUnder the terms of the agreement, ArcelorMittal expects to receive an aggregate equity value consideration of $1.4 billion upon closing of the Transaction. Approximately one third of the consideration is in upfront cash ($505 million). The remaining two thirds of the consideration is in the form of equity: stock component of approximately 78 million...
Yleiselektroniikan yhteistoimintaneuvottelut Suomessa päätökseen
Written by Customer Service on . Posted in Public Companies.
YLEISELEKTRONIIKKA OYJ Sisäpiiritieto 28.9.2020 klo 08:30Yleiselektroniikan yhteistoimintaneuvottelut Suomessa päätökseenYleiselektroniikka- konserni on saanut päätökseen 11.8.2020 käynnistetyt yhteistoimintaneuvottelut. Neuvottelut koskivat Yleiselektroniikka Oyj:n ja Machinery Oy:n koko Suomen henkilöstöä, yhteensä noin 140 henkilöä, ja ne käynnistettiin liiketoimintojen ja organisaation uudelleenjärjestelemiseksi sekä toimintojen tehostamiseksi. Suunniteltujen toimenpiteiden ilmoitettiin johtavan arviolta 30 henkilön vähennystarpeeseen.Päättyneiden neuvottelujen seurauksena irtisanotaan enintään 23 henkilöä vuoden 2020 loppuun mennessä. Irtisanomisten lisäksi konsernista vähenee seitsemän positiota muun muassa neuvottelujen aikana tapahtuneiden irtisanoutumisten ja eläköitymisten seurauksena.YT- neuvottelut olivat osa...
Basilea starts phase 1/2 study FIDES-03 with derazantinib in patients with gastric cancer
Written by Customer Service on . Posted in Public Companies.
Basel, Switzerland, September 28, 2020Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has initiated the phase 1/2 study, FIDES-03, with the FGFR inhibitor derazantinib. The multi-cohort study is evaluating derazantinib in patients with advanced gastric cancer with FGFR genetic aberrations. Derazantinib will be assessed as monotherapy and in combination with other cancer treatments, for instance with Roche’s PD-L1 checkpoint inhibitor, atezolizumab.Basilea will be the sponsor of the study and Roche will provide clinical supply of atezolizumab.Dr. Marc Engelhardt, Basilea’s Chief Medical Officer, said: “Our development strategy for derazantinib is focused on strengthening the clinical evidence on the differentiation versus other FGFR inhibitors. The unique kinase inhibition profile of derazantinib, results from preclinical...
Basilea beginnt Phase-1/2-Studie FIDES-03 mit Derazantinib bei Patienten mit Magenkrebs
Written by Customer Service on . Posted in Public Companies.
Basel, 28. September 2020Basilea Pharmaceutica AG (SIX: BSLN) gab heute den Beginn der Phase-1/2-Studie FIDES-03 mit dem FGFR-Inhibitor Derazantinib bekannt. Die Multikohorten-Studie erprobt Derazantinib bei Patienten mit fortgeschrittenem Magenkrebs, deren Tumore Veränderungen (Aberrationen) im FGFR-Gen aufweisen. Derazantinib soll sowohl als Mono- als auch als Kombinationstherapie, beispielsweise mit Roches PD-L1-Checkpoint-Inhibitor Atezolizumab, untersucht werden. Basilea übernimmt als Sponsor die Leitung der Studie, während Roche Atezolizumab für die Studie zur Verfügung stellen wird.Dr. Marc Engelhardt, Basileas Chief Medical Officer, sagte: „Unsere Entwicklungsstrategie für Derazantinib ist darauf ausgerichtet, die klinische Evidenz für die Differenzierung gegenüber anderen FGFR-Inhibitoren zu stärken. Das einzigartige Kinasen-Inhibitionsprofil...
